NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, News, & Analysis

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported $0.00 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.01. The biotechnology company earned $11.69 million during the quarter, compared to analyst estimates of $13.46 million. Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. View Pieris Pharmaceuticals' Earnings History.

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Pieris Pharmaceuticals.

5 Wall Street analysts have issued twelve-month price objectives for Pieris Pharmaceuticals' shares. Their predictions range from $12.00 to $13.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $12.3333 in the next twelve months. This suggests a possible upside of 128.0% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

Pieris Pharmaceuticals saw a drop in short interest in August. As of August 31st, there was short interest totalling 2,492,106 shares, a drop of 39.2% from the August 15th total of 4,097,736 shares. Based on an average daily volume of 306,916 shares, the short-interest ratio is presently 8.1 days. Currently, 4.7% of the shares of the company are short sold. View Pieris Pharmaceuticals' Current Options Chain.

Some companies that are related to Pieris Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), HedgePath Pharmaceuticals (HPPI), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), Vitality Biopharma (VBIO), Dyadic International (DYAI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), Protalex (PRTX) and US Stem Cell (USRM).

Media stories about PIRS stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Pieris Pharmaceuticals.

Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (5.81%), BlackRock Inc. (4.97%), Acadian Asset Management LLC (3.94%), Aquilo Capital Management LLC (3.66%), Prosight Management LP (2.52%) and Millennium Management LLC (2.00%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Trexquant Investment LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, BlackRock Inc., Prosight Management LP, Acadian Asset Management LLC, American Century Companies Inc., GSA Capital Partners LLP, Spark Investment Management LLC and Assenagon Asset Management S.A.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $5.41.

Pieris Pharmaceuticals has a market capitalization of $269.63 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]